1) Young Professionals Scheme: It was conceived as part of an India-U.K. Migration and Mobility MoU signed in May 2021 and was announced in November at the G20 summit in Bali.
- It will permit up to 3,000 of their degree-holding citizens aged between 18 and 30 to live and work in each other’s countries for two years.
- The programme will be reciprocal, also allowing UK professionals in the same position to participate in a professional exchange by living and working in India.
- This scheme makes India the first visa-national country to benefit from the scheme.
2) SPRINT Scheme: To achieve ‘Aatmanirbharta’ in defence, Naval Innovation and Indigenisation Organisation (NIIO), in conjunction with the Defence Innovation Organisation (DIO), aims to induct at least 75 new indigenous technologies/products into the Indian Navy till august 2023.
- This collaborative project is named SPRINT {Supporting Pole-Vaulting in R&D through Innovations for Defence Excellence (iDEX)
- It was launched in 2022 and will transform Navy from a ‘Buyer’s Navy’ to a ‘Builder’s Navy.
3) Article 176: The Governor shall address the Legislative Assembly or both Houses (in the case of a State having a Legislative Council), assembled together at the
- Commencement of the first session after each general election to the Legislative Assembly and Commencement of the first session of each year
- Provision shall be made by the rules regulating the procedure of the House or either House for the allotment of time for discussion of the matters referred to in such address.
4) Duchenne Muscular Dystrophy: It is the most common and fatal type of muscular dystrophy marked by progressive muscle degeneration and weakness due to alterations of a protein called “dystrophin” that helps keep muscle cells intact.
- Patients: usually children have reduced bone density (mostly boys, and rarely girls)
- India has over 5 lakh patients. The current therapeutic options available to treat DMD are minimal and highly expensive treatment and are mostly imported from abroad.
- A research team is working to replace Antisense Oligonucleotide (AON)-based therapeutics’ idea (to mask specific exons in a gene sequence) with molecular tags, so that customised/personalised medicine can be developed.
- Researchers have made progress in the development of generic Utrophin Modulators.
- Utrophin and Dystrophin can co-localise in human muscle. Utrophin overexpression could act as a surrogate, compensating for the lack of dystrophin.
5) Appointment of High court judges:
